Literature DB >> 15936607

C-reactive protein and electrocardiographic ST-segment depression additively predict mortality: the Strong Heart Study.

Peter M Okin1, Mary J Roman, Lyle G Best, Elisa T Lee, James M Galloway, Barbara V Howard, Richard B Devereux.   

Abstract

OBJECTIVES: This study was designed to examine whether high-sensitivity C-reactive protein (CRP) and electrocardiographic (ECG) ST-segment depression (STD) have additive utility for predicting cardiovascular disease (CVD) death and all-cause death (ACD).
BACKGROUND: C-reactive protein, a marker of systemic inflammation, and ECG STD, an index of myocardial ischemia and hypertrophy, independently predict mortality.
METHODS: Electrocardiograms and CRP levels were examined in 2,155 American Indian participants in the second Strong Heart Study examination. ST-segment depression >/=50 microV (n = 127) and CRP >7.0 mg/l (defining the upper quartile of CRP levels, n = 540) were considered abnormal.
RESULTS: After 5.2 +/- 1.2 years follow-up there were 95 CVD deaths and 310 ACD. In univariate Cox analyses, the combination of CRP and ECG STD improved risk stratification compared to either alone, with the presence of both CRP >7.0 and ECG STD associated with a 7.7-fold increased risk of CVD death (95% confidence interval [CI] 3.3 to 18.2) and a 6.5-fold increased risk of ACD (95% CI 4.1 to 10.3). After adjustment for age, gender, and relevant risk factors, the combination of high CRP and STD remained predictive of CVD death and ACD, with the presence of both abnormal CRP and STD associated with the highest risks of CVD death (hazard ratio [HR] 3.2, 95% CI 1.1 to 10.5) and ACD (HR 3.9, 95% CI 2.1 to 7.2) and the presence of either high CRP or abnormal STD associated with intermediate risks of CVD death (HR 2.2, 95% CI 1.4 to 3.4) and ACD (HR 1.5, 95% CI 1.2 to 2.0).
CONCLUSIONS: The combination of ECG STD and CRP increases the risk of mortality, demonstrating the additive impacts of active inflammation and preclinical CVD on prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936607     DOI: 10.1016/j.jacc.2005.02.072

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

Review 1.  Primary prevention for patients with intermediate Framingham risk scores.

Authors:  Jason B Thompson; Juan J Rivera; Roger S Blumenthal; Peter Danyi
Journal:  Curr Cardiol Rep       Date:  2006-07       Impact factor: 2.931

2.  Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection.

Authors:  Mihir Gupta; Christopher J Miller; Jason V Baker; Jason Lazar; Johannes R Bogner; Alexandra Calmy; Elsayed Z Soliman; James D Neaton
Journal:  Am J Cardiol       Date:  2012-12-29       Impact factor: 2.778

3.  Ambient fine particulate matter exposure and myocardial ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative (EEAWHI) study.

Authors:  Zhu-Ming Zhang; Eric A Whitsel; P Miguel Quibrera; Richard L Smith; Duanping Liao; Garnet L Anderson; Ronald J Prineas
Journal:  Environ Health Perspect       Date:  2009-01-23       Impact factor: 9.031

4.  Relation between Oral Health Status and Electrocardiogram ST Segment Changes in a Group of Patients with Myocardial Infarction.

Authors:  Atousa Aminzadeh; Masoud Ahmadi; Sayyed Mohsen Hosseini
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2013-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.